How does artificial intelligence help the development of new drugs? Academicians explain opportunities and challenges
Artificial intelligence will bring more hope to the research and development of new drugs. According to Yingsi Intelligent's "2022 Artificial Intelligence Drug Research and Development White Paper", in the past five years, artificial intelligence technology has greatly enhanced the efficiency of new drug research and development, and the drug screening time has been reduced from five years to three. In 2017, the clinical success rate increased from 12% to 14%. Today, at the 2023 "Chunsheng Cup" Medical Innovation Talent Competition Award Ceremony and Shanghai Medical Innovation Forum organized by the Municipal Health Commission, Professor Chen Kaixian, an academician of the Chinese Academy of Sciences, brought data and said that artificial intelligence helps the research and development of new drugs, and will also be used in traditional Chinese medicine compound formulations in the future. Research and other areas continue to be explored.
To develop the biomedical industry in our country, strengthening original innovation in new drug research is key. In the keynote speech of the forum, Academician Chen introduced: Original innovation is to achieve a breakthrough "from 0 to 1", open up a new track, and sort out the connotation of original innovation, which mainly includes new treatment concepts and strategies, new targets, new mechanisms, new technologies, and new structural types. , new indications, new dosage forms and drug delivery systems, etc.
In recent years, the R&D investment of innovative biopharmaceutical companies has grown very rapidly, with some even exceeding that of large traditional comprehensive pharmaceutical companies, and their pipelines under research and development have also gradually enriched. Judging from the R&D investment of listed pharmaceutical companies in 2022, BeiGene, Hengrui Pharmaceuticals, Fosun Pharma, CSPC Pharmaceutical Group, and Chi-Med Pharmaceuticals rank among the top five. Among the pipelines of the top 20 innovative biopharmaceutical companies in my country that invest in R&D, they are still dominated by Phase I and Phase II, which have not yet reached the harvest period. Among them, clinical phase I accounts for 44.92%, clinical phase II accounts for 20.52%, and clinical phase III accounts for 44.92%. Compared with 12.38%, another 3.14% applied for listing and 16.54% have been approved for listing.
Academician Chen believes that artificial intelligence technology has great potential in assisting drug research and development. Taking the technological innovation of traditional Chinese medicine compound research as an example, development faces three key technical problems: identification technology of active ingredient groups, technology evaluation technology of efficacy-effect correlation of active ingredient groups, and quantitative formulation design technology of active ingredient groups. He said that drug mixtures are often more effective than individual drugs, but due to the extremely large number of possible combinations and the extremely complex biological action network, it is very challenging to determine a potent drug combination through "trial and error", and The above problems can be solved by using artificial intelligence.
In innovative drug research and development, artificial intelligence technology can participate in the entire process. Specifically, it ranges from discovering disease mechanism targets, predicting protein structures, discovering biomarkers, optimizing drug structures, and predicting drug activity, to optimizing antibodies, establishing drug knowledge maps, and even patient disease progression and predicting clinical success rates. For this reason, McKinsey & Company predicts that one of the top ten development trends of artificial intelligence is that new drugs and treatments can be obtained quickly and at low cost through artificial intelligence technology.
Nowadays, generative artificial intelligence models have been explored in drug research and development. Academician Chen believes that some ethical considerations should also be treated with caution. For example, generative artificial intelligence can indeed achieve faster and better innovation, but it has certain limitations in drug research and development, and data quality, multi-modality, accessibility and privacy protection face challenges; in addition, the explanation ability of large models, Credibility requires sufficient evidence. Data sample collection has its limitations. Whether it complies with regulations and ethics is also worthy of scrutiny.
Looking to the future, the application of artificial intelligence technology in drug research and development can be more widely explored. For example, generative artificial intelligence combined with automation technology can complete the efficient and precise synthesis and continuous manufacturing of drug molecules; another example is simulated clinical processes and digital drug research and development, etc.
At the forum, Zhang Jie, chief technology officer of Shanghai MicroPort Medical Devices Co., Ltd., also gave a keynote speech. Professor Ge Junbo, academician of the Chinese Academy of Sciences, Xue Yueqiang, vice president of R&D of Biomedical Greater China, Yu Yeheng, senior vice president and chief brand officer of Shanghai United Imaging Medical Technology Co., Ltd., Ji Dongmei, founding management partner of Gimpo Health Fund, Shanghai Huitian Medical Technology Co., Ltd. The company's CEO and founder Lin Lin and the 2023 "Chunsheng Cup" first prize winner Zhao Jie, director of the Department of Orthopedics of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, attended the roundtable forum.
It is reported that the "Chunsheng Cup" Medical Innovation Talent Competition is one of the activities of the 2023 Shanghai International Biomedical Industry Week. Since it was first held last year, it has received widespread attention and active participation from all walks of life. This year's competition attracted 182 project registrations from 66 universities and medical and health institutions. After the preliminary round, semi-finals and finals, a total of 12 projects were selected for first, second and third prizes. At the same time, the meeting held the awarding of the Intellectual Property Operation Center of the Shanghai Medical and Health System, the appointment of representatives of the "Offshore Medical Upgrading" special enterprise think tank, and the release of the 2023 "Offshore Medical Upgrading" clinical research project.
The relevant person in charge of the Municipal Health Commission said that they will also organize medical enterprise matchmaking meetings to build a service bridge between industry, academia, and research, further smoothen the interaction channels between medical enterprises, and provide professional technical services such as technology evaluation of patent results, technology intermediary, and transformation process policy consultation. , to achieve accurate docking of projects and capital.
![How does artificial intelligence help the development of new drugs? Academicians explain opportunities and challenges](https://a5qu.com/upload/images/dff4bf1ed400e42ca88fa1d24dff7e6f.webp)